Ionis Pharmaceuticals Inc. (NASDAQ:IONS) partner GSK Plc (NYSE:GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (CHB). The studies included over 1,800 patients.GSK licensed bepirovirsen from Ionis in 2019. The two companies have collaborated on its development.Under the terms of the agreement, Ionis received an upfront payment, license fee, and development milestone payments, and is el ...